g or relating to our
future financial results and guidance, statements regarding expectations
and anticipated changes in product mix between business segments,
statements regarding factors that will affect our cost of revenues and
gross margins, statements regarding our beliefs about future demand,
volumes and average prices for Grade I AP, our Fine Chemicals segment's
order and operations levels, statements regarding our expectations for
demand for sodium azide, statements regarding our expectations for Holotron
volumes, statements relating to our expectations for revenue growth in our
Aerospace Equipment segment, statements regarding our working capital
changes and future variations, and all statements in the "Outlook" section
of this earnings release. Words such as "anticipate", ""expect", "should",
"may", "can", "will" and similar expressions are intended to identify
forward-looking statements. The inclusion of forward-looking statements
should not be regarded as a representation by the Company that any of its
expectations will be achieved. Actual results may differ materially from
those set forth in the release due to risks and uncertainties inherent in
the Company's business. Factors that might cause such differences include,
but are not limited to, the following:
-- We depend on a limited number of customers for most of our sales in our
Specialty Chemicals, Aerospace Equipment and Fine Chemicals segments
and the loss of one or more of these customers could have a material
adverse affect on our revenues.
-- The inherent limitations of our fixed-price or similar contracts may
impact our profitability.
-- The numerous and often complex laws and regulations and regulatory
oversight to which our operations and properties are subject, the cost
of compliance, and the effect of any failure to comply could reduce our
profitability and liquidity.
-- A significant portion of o
'/>"/>
SOURCE American Pacific Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Related medicine news :1.
Data From Antheras Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions2.
American Red Cross Responds to Tornadoes in the Southeast3.
Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology4.
Massive American Red Cross Tornado Relief Effort Spans Five States5.
Sodium Content Foods and Beverages Gain Revenues as Americans are Embracing Low- and No-Sodium Campaigns6.
Vitals.com Goes Red for American Heart Month7.
American Heart Month: Cracking Open Heart Health Myths8.
Consumer Reports Poll: Americans Demand Health Reform But Are Unsure About How to Achieve it9.
Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal10.
Senetek PLC Announces Debut of Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology11.
Shareholder Class Action Filed Against American Dental Partners, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP